Pfizer Boost FY24 Outlook - Update

RTTNews | 112 dias atrás
Pfizer Boost FY24 Outlook - Update

(RTTNews) - While reporting financial results for the second quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings and revenue guidance for the full-year 2024.

For fiscal 2024, the company now projects adjusted earnings in a range of $2.45 to $2.65 per share on revenues between $59.5 billion and $62.5 billion, with revenues of about $8.5 billion for Comirnaty, about $5 billion for Paxlovid and about $3.5 billion from legacy Seagen.

Previously, the company expected adjusted earnings in the range of $2.15 to $2.35 per share on revenues between $58.5 billion and $61.5 billion, with revenues of about $5 billion for Comirnaty, about $3 billion for Paxlovid and about $3.1 billion from legacy Seagen.

On average, 21 analysts polled by Thomson Reuters expect the company to report earnings of $2.38 per share on revenues of $60.70 billion for the year. Analysts' estimates typically exclude special items.

Including the contribution from Seagen and excluding revenues from Comirnaty and Paxlovid, Pfizer now expects to achieve full-year 2024 operational revenue growth of 9 to 11 percent, compared to 2023 revenues, up from 8 to 10 percent provided on January 30, 2024.

The company has launched a manufacturing optimization program with anticipated cost savings of approximately $1.5 billion by the end of 2027.

The company is also on track to deliver at least $4 billion in net cost savings by end of 2024 from previously announced cost realignment program.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com

Marcadores : PFE
read more
Pfizer Launches Digital Platform PfizerForAll

Pfizer Launches Digital Platform PfizerForAll

Drug giant Pfizer Inc. (PFE) announced Tuesday the introduction of PfizerForAll, a user-friendly digital platform designed to make access to healthcare and managing health and wellness more seamless for people across the U.S.
RTTNews | 84 dias atrás
FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants

FDA Approves Updated Pfizer, Moderna Covid Vaccines Against Current Variants

The U.S. Food and Drug Administration approved and granted emergency use authorization or EUA for updated Covid vaccines from Pfizer Inc. and ModernaTX Inc. for use against currently circulating variants. The approval for the updated mRNA COVID-19 vaccines (2024-2025 formula) comes as the Covid cases are surging in the United States.
RTTNews | 88 dias atrás
Pfizer's Hospira Recalls Select Hydrochloride Injection Carpuject Units

Pfizer's Hospira Recalls Select Hydrochloride Injection Carpuject Units

Hospira, Inc., affiliated to dug major Pfizer Inc., is recalling select lots of Buprenorphine Hydrochloride Injection Carpuject Units and Labetalol Hydrochloride Injection Carpuject Units, according to the U.S. Food and Drug Administration. The recall was initiated due to the potential for incomplete crimp seals. The company has received one customer complaint for one leaking unit.
RTTNews | 180 dias atrás
Amazon, Microsoft, Pfizer To Invest Billions In French Projects

Amazon, Microsoft, Pfizer To Invest Billions In French Projects

Major companies, including Amazon.com Inc., Microsoft Corp., Morgan Stanley, Pfizer and others, have announced around 15 billion euros or $16.2 billion worth foreign investments in France as part of the country's annual 'Choose France' business summit, reports said. French President Emmanuel Macron kicks off the summit of 180 CEOs and executives on Monday, aiming to showcase foreign investment.
RTTNews | 190 dias atrás
Pfizer Boost FY24 Adj. EPS Outlook - Update

Pfizer Boost FY24 Adj. EPS Outlook - Update

While reporting financial results for the first quarter, drug major Pfizer Inc. (PFE) raised its adjusted earnings guidance for the full-year 2024, while maintaining annual revenue outlook.
RTTNews | 202 dias atrás
Pfizer Closes $43 Bln All-cash Acquisition Of Seagen

Pfizer Closes $43 Bln All-cash Acquisition Of Seagen

Pfizer Inc. (PFE) announced Thursday the successful completion of its acquisition of biotechnology company Seagen Inc. (SGEN). Pfizer completed its acquisition of all outstanding common stock of Seagen for $229 in cash per share, for a total enterprise value of approximately $43 billion.
RTTNews | 341 dias atrás